Longevity
Thymosin Alpha 1
Immunity
28
Amino acids
Molecular weight
Peptide
Type
Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.
Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.
Use immediately after reconstitution or refrigerate up to 2 hours
2x weekly (e.g., Monday and Thursday) for standard immune support
1.6mg per injection (standard dose across all protocols)
6 months continuous for therapeutic protocols
Primary FDA-studied route with extensive clinical validation
Maximum immune modulation through systemic circulation
Established dosing from 35+ countries of clinical use
Exceptional safety profile (<1% serious adverse events)
Reduces pro-inflammatory cytokines 40-60%
Approved in 35+ countries
This peptide is still gaining traction in the community.
Synthetic Thymic Hormone | Immune System Modulator
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesView the scientifc details of Thymosin Alpha 1.
28
Amino Acids
Thymosin Alpha 1
Ser
Ser
Position 1
Asp
Asp
Position 2
Ala
Ala
Position 3
Ala
Ala
Position 4
Val
Val
Position 5
Asp
Asp
Position 6
Thr
Thr
Position 7
Ser
Ser
Position 8
Ser
Ser
Position 9
Glu
Glu
Position 10
Ile
Ile
Position 11
Thr
Thr
Position 12
Thr
Thr
Position 13
Lys
Lys
Position 14
Asp
Asp
Position 15
Leu
Leu
Position 16
Lys
Lys
Position 17
Glu
Glu
Position 18
Lys
Lys
Position 19
Lys
Lys
Position 20
Glu
Glu
Position 21
Val
Val
Position 22
Val
Val
Position 23
Glu
Glu
Position 24
Glu
Glu
Position 25
Ala
Ala
Position 26
Glu
Glu
Position 27
Asn
Asn
Position 28
Subcutaneous injection is the primary route with 90-95% bioavailability. Standard dosing is 1.6mg twice weekly.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Standard immune support | 1.6 | 2 week range | SubQ |
| Acute conditions (sepsis) | 1.6 | 2 week range | SubQ/IM |
| Cancer/hepatitis support | 1.6 | 2 week range | SubQ |
| Maintenance/prevention | 1.6 | 2 week range | SubQ |
Materials needed:
Steps to reconstitute
The Thymosin Alpha 1 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
Dosing tools
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Based on your vial and dilution inputs.
Thymosin Alpha 1
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Thymosin Alpha 1 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Note: Triple agonist; microdose for fewer side effects
Organ transplant recipients (risk of graft rejection)
Pregnancy and breastfeeding
Signs of graft rejection in transplant recipients
Persistent injection site reactions or infection signs
Unusual immune system hyperactivity
Severe allergic reactions (rare)
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
Thymosin Alpha 1 is a well studied compound
Thymosin Alpha 1
Thymosin Alpha 1 is a well studied compound
COVID-19 Treatment Study
30% vs 11% mortality reduction in severe cases; lymphocyte restoration.
2020
TESTS Phase 3 Sepsis Trial
1,106 patients; mixed overall results but subgroup benefits in elderly/diabetic populations.
2020
Cytokine Storm Mitigation Study
40-60% reduction in pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).
2020
Comprehensive Safety Review
11,000+ patients, 30+ trials; <1% serious adverse events.
2024